Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902184 · ClinicalTrials.gov registry record · Phase 2
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
A Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous, sponsored by Innate Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT03902184 is a Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous that is active but no longer recruiting, run by Innate Pharma. The registered enrollment target is 170 participants, above the 107-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03902184, a Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous, is active but no longer recruiting, sponsored by Innate Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Conditions Studied
Interventions
- BIOLOGICAL IPH4102
Study Locations (20)
California
- University of California, Los Angeles (UCLA) - Medical Center - Los Angeles
- Irvine Medical Center - Orange
- Stanford University - Stanford
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
Other
- Universitätsklinik für Dermatologie Medizinische Universität Graz - Graz
- Medizinische Universitaet Wien - Vienna
- Institut Jules Bordet - Brussels
Florida
- Moffitt Cancer Center - Tampa
- University of South Florida - Tampa
New York
- Universal Dermatology, PLLC68 - Fairport
- Columbia University Department of Dermatology - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- Northwestern University The Feinberg School of Medicine - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03902184
The ClinicalTrials.gov registry entry for NCT03902184 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (59% higher). The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma, T-Cell appearing as the primary indexed condition, and to 1 intervention - of which IPH4102 is the first listed.
NCT03902184 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT03902184 about?
NCT03902184 is a clinical study titled "IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma". This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
What is the current status of trial NCT03902184?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2019-05-22. Estimated completion is 2026-01-31.
What conditions does trial NCT03902184 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome.
What interventions are being tested in trial NCT03902184?
The interventions under investigation include: IPH4102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03902184?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03902184 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
COMPLETED · Phase 2
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.